130483-44-2

Upstream product

• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 107-30-2 chloromethyl methyl ether 
• 914298-92-3 methyl 2,4-dimethoxymethyloxybenzoate 
• 1165713-26-7 methyl 2-(4-methoxy-benzyloxy)-4-methoxymethyloxybenzoate 

Downstream Products

• 959466-40-1 C₉H₁₂N₂O₄ 
• 1165713-24-5 methyl 2-benzyloxy-4-methoxymethyloxybenzoate 
• 1165713-21-2 methyl 2-isopropoxy-4-methoxymethyloxybenzoate 
• 1165713-26-7 methyl 2-(4-methoxy-benzyloxy)-4-methoxymethyloxybenzoate 
• 1041191-23-4 methyl 4-(methoxymethoxy)-2-(oxiran-2-ylmethoxy)benzoate 

Relevant academic research and scientific papers

NO Donor coumarin furoxan conjugates and pharmaceutical use thereof

The invention belongs to the technical field of chemical pharmacy. Experiments prove that the furoxan conjugate has good water 3 - solubility, has excellent inhibitory activity on the growth of sensitive human tumor cells and resistant tumor cells, and NO

Thienopyrimidines as β3-adrenoceptor agonists: Hit-to-lead optimization

Resulting from a vHTS based on a pharmacophore alignment on known β3-adrenoceptor ligands, an aryloxypropanolamine scaffold comprising a thienopyrimidine moiety was further optimized as a human β3-AR agonist, yielding a lead compound with an excellent cellular activity of EC50 = 20 pM, selectivity over hβ1- and hβ2-adrenoceptors and a promising safety profile.

Factors affecting orthogonality in the deprotection of 2,4-di-protected aromatic ethers employing solid-supported acids

Selective deprotection of aromatic ethers bearing two protecting groups on the same aromatic ring by solid-supported acids (Amberlyst-15 and PTS-Si) was systematically investigated. ortho-Directing protonation by the carbonyl group as well as carbocation stability and quenching are the important determining factors for the orthogonal deprotection process. Stablilized carbocations (e.g., those from the MOM and PMB groups) could be removed with high selectivity.

Triazole compounds that modulate Hsp90 activity

The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound.

Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments

This invention relates to novel aryloxypropanolamines. The invention also relates to the pharmaceutically acceptable salts and solvates containing said compounds, methods for the preparation thereof and to respective synthesis intermediates. Said compound